Contaminated cough syrups: a danger from India
The World Health Organization (WHO) recently sounded the alarm over the presence on the market of a batch of contaminated cough syrup. This product, called Cold Out, was discovered in Iraq but manufactured in India.
Tests revealed that this batch of cough suppressants contained excessive amounts of Diethylene Glycol and Ethylene Glycol, well in excess of the limit of 0.10%. These substances are highly toxic and their ingestion can cause serious health problems or even death.
Despite the various warnings from the WHO, the manufacturer and distributor of Cold Out have still not provided the necessary guarantees regarding the safety of this medicine. This situation is all the more worrying given that last year, consumption of syrups made in India was linked to the deaths of at least 89 children in Gambia and Uzbekistan. Similar cases have also been reported in Cameroon.
The Indian firms in question dispute these accusations and assert that their products comply with safety standards. However, the scientific evidence and the numerous cases of deaths linked to the consumption of these syrups cannot be ignored.
It is essential that health authorities take strict measures to prevent the circulation of these contaminated medicines on the market. Quality controls must be strengthened and severe sanctions must be taken against manufacturers and distributors who do not comply with safety standards.
In the meantime, it is essential to be vigilant when purchasing any medicine, ensuring that it comes from reliable sources and has clear traceability. Consumer health and safety must always be the top priority.
It is also crucial to increase public awareness of the potential dangers of counterfeit or contaminated medicines. Consumers must be informed of the risks involved and encouraged to report any adverse reactions or suspected defective products to the competent authorities.
In conclusion, the presence of contaminated cough syrups on the market is a serious problem that requires urgent action. The health and safety of individuals must be protected, and this requires rigorous quality controls and appropriate sanctions. Let’s not let counterfeit medicines endanger the lives of those who consume them.